EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA)
Introduction
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as ADB-CHMINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.
Download as PDF
Table of contents
- Introduction
- Information collection process
- Information required by Article 5.2 of the Council Decision
- Information from the EMA (Article 5.3 of the Council Decision)
- Conclusion
- References
Pages:
15
Price:
Free
ISBN:
978-92-9497-206-4
ISSN:
1977-7868
Pub. DOI:
10.2810/41095
Catalog Number:
TD-AS-17-006-EN-N
Main subject